3 results
Approved WMORecruiting
Primary objective:To continue assessing the safety and tolerability of ANAVEX2-73.Safety and Tolerability Measures:* Physical examination* Vital signs (heart rate, respiratory rate, systolic blood pressure [SBP], diastolic blood pressure [DBP],…
Approved WMORecruiting
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…
Approved WMORecruiting
1. To evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period